Carolyn Bertozzi-founded Lycia Therapeutics raises $106M to enter the clinic
13 May 2024
PROTACs
A different take on protein degradation will enter human trials as Lycia Therapeutics, founded by Nobel laureate Carolyn Bertozzi, has refueled with $106.6 million.
The Series C, disclosed Monday morning, will fund lead programs in autoimmune and inflammatory diseases. The biotech is also still working with investor and partner Eli Lilly on up to five different targets in immunology and pain, a $1.6+ billion pact that was disclosed a few weeks before a $70 million Series B in the fall of 2021.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.